Dublin, Ireland-based Trinity unveiled the CGM+ next-gen wearable biosensor in July 2025. With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages of device development. The new AI-native CGM combines multi-sensor data with real-time analytics to meet the evolving demands of AI-powered healthcare and wellness. It could offer a fingerstick-free, calibration-free CGM option amid a competitive market.
New clinical study results highlighted the ability of CGM+ to identify nocturnal compression-related false low glucose events. The company says this represents a common limitation of conventional CGMs. It believes findings further validate its CGM+ architecture and its ability to deliver valuable physiological context alongside glucose measurements.
Trinity Biotech said its multi-sensor wearable platform combines glucose measurements with additional metrics and AI-driven analytics. It has the CGM+ in the latter stages of development and expects to incorporate the nocturnal compression low function ahead of pivotal trial and regulatory efforts.
Earlier this year, the company said it intends to initiate a pivotal trial later this year, with regulatory submissions expected thereafter.
More about the clinical findings shared by Trinity Biotech
The analysis used approximately 5,000 hours of device wear data. It collected data from insulin-dependent people with diabetes during a pre-pivotal clinical trial completed during the second quarter of 2026.
By combining glucose measurements with additional physiological signals captured through a proprietary sensor architecture integrated within the CGM+ platform, Trinity Biotech developed an algorithm designed to distinguish false low glucose readings caused by sensor compression during sleep from true changes in blood glucose levels.
The company said its findings demonstrate CGM+’s ability to deliver physiological context not available in traditional glucose-only CGMs. It hopes to address real-world pain points like false alarms, sleep disruption and avoidable glucose variability. Additionally, it wants to offer automated insulin delivery system makers richer, more contextual data.
John Gillard, president and CEO of Trinity Biotech, said:
“CGM+ was designed from the outset to go beyond glucose measurement, by delivering a single wearable device that combines the benefits of continuous glucose monitoring with broader physiological data points, such as heart activity, body temperature, and physical activity. These clinical results further validate that approach and our goal of delivering insights, not just data.
“Based on direct conversations with CGM users on their pain points and engagement with the broader ecosystem, we believe real-time identification of nocturnal compression-related false lows addresses an important limitation of glucose-only systems and demonstrates how CGM+ can improve the user experience, strengthen our commercial opportunity and provide richer data to automated insulin delivery partners.”
